The estimated Net Worth of Deventer Sander Van is at least $784 Mille dollars as of 28 January 2020. Sander Van owns over 2,227 units of Hookipa Pharma Inc stock worth over $227,711 and over the last 8 years he sold HOOK stock worth over $290,627. In addition, he makes $265,291 as Independent Director at Hookipa Pharma Inc.
Sign up
Sander Deventer HOOK stock SEC Form 4 insiders trading
Sander has made over 5 trades of the Hookipa Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,227 units of HOOK stock worth $137,205 on 28 January 2020.
The largest trade he's ever made was buying 1,545,454 units of Hookipa Pharma Inc stock on 2 August 2016 worth over $8,159,997. On average, Sander trades about 151,455 units every 69 days since 2016. As of 28 January 2020 he still owns at least 43,127 units of Hookipa Pharma Inc stock.
You can see the complete history of Sander Van stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sander van Deventer biography
Dr. Sander J.H. van Deventer M.D. Ph.D. serves as Independent Director of the Company. r. van Deventer has been a general partner of Forbion Capital Partners (formerly ABN AMRO Capital) since 2006. He has also been the Chief Scientific Officer of uniQure since August 2017. From 2008 to 2009, he served as the Chief Executive Officer of Amsterdam Molecular Therapeutics, or AMT, a gene therapy company that he co-founded in 1998. From 2012 to 2013, he was the Chief Executive Officer of Dezima Pharma, which was acquired by Amgen Inc. In addition, Dr. van Deventer has also served as a member of AMT's board of directors since 2007. He previously served as a member of the board of directors of Argos Therapeutics, Inc. from 2001 until 2018 and a member of the board of directors of uniQure from February 2014 until August 2018. Our Board of Directors believes that Dr. van Deventer's experience serving on the boards of directors of life science companies and his experience in venture capital qualify him to serve on our Board of Directors.
What is the salary of Sander Deventer?
As the Independent Director of Hookipa Pharma Inc, the total compensation of Sander Deventer at Hookipa Pharma Inc is $265,291. There are 6 executives at Hookipa Pharma Inc getting paid more, with Joern Aldag having the highest compensation of $6,367,980.
How old is Sander Deventer?
Sander Deventer is 65, he's been the Independent Director of Hookipa Pharma Inc since 2011. There are 1 older and 16 younger executives at Hookipa Pharma Inc. The oldest executive at Hookipa Pharma Inc is Prof. Rolf M. Zinkernagel M.D., Ph.D., 77, who is the Co-Founder.
What's Sander Deventer's mailing address?
Deventer's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC.,, 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10118.
Insiders trading at Hookipa Pharma Inc
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... e Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
What does Hookipa Pharma Inc do?
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
What does Hookipa Pharma Inc's logo look like?
Complete history of Sander Van stock trades at uniQure N.V e Hookipa Pharma Inc
Hookipa Pharma Inc executives and stock owners
Hookipa Pharma Inc executives and other stock owners filed with the SEC include:
-
Joern Aldag,
Chief Executive Officer, Director -
Reinhard Kandera,
Chief Financial Officer, Director -
Igor Matushansky,
Chief Medical Officer and Global Head of Research and Development -
Joern Aldag,
CEO & Director -
Dr. Igor Matushansky M.D., Ph.D.,
Chief Medical Officer and Global Head of R&D -
Dr. Reinhard Kandera,
CFO & Director -
Sander van Deventer,
Independent Director -
Graziano Seghezzi,
Independent Director -
Jan van de Winkel,
Independent Chairman of the Board -
Michael Kelly,
Independent Director -
David Kaufman,
Independent Director -
Christoph Lengauer,
Independent Director -
Julie O Neill,
Independent Director -
Jean-Charles Soria,
Director -
Roman Necina,
Chief Technology Officer -
Klaus Orlinger,
Executive Vice President - Research -
Dr. Klaus Orlinger Ph.D.,
Exec. VP of Research -
Nina Waibel,
Sr. Director of Communications -
Marine Popoff,
Communications & Investor Relations Mang. -
Dr. Roman Necina Ph.D.,
Chief Technology Officer -
Lukas Flatz,
Co-Founder -
Andreas Bergthaler,
Co-Founder -
Prof. Rolf M. Zinkernagel M.D., Ph.D.,
Co-Founder -
Jerry D Jones,
Director -
Bros. Advisors Lp Baker Bro...,
-
Capital Fund Ii Cooperatief...,
10% owner -
David Pinschewer,
Chief Scientific Officer -
Group, Llc Green Jeremy Red...,
-
Capital Vi Fcpr Sofinnova P...,
-
Anders Lilja,
Sr. VP, Technical Development -
Timothy P. Reilly,
-
Andrew R Goeler,
Director -
Mark D Moreland,
Chief Financial Officer -
John D Jr Rogers,
Director -
Martin J Iv Wall,
Vice President, Sales -
David R Lord,
Director -
V Sebastian Pastore,
VP, Brewing Operations & Tech -
Marc J Cramer,
Director -
Terry E Michaelson,
Co-Chief Executive Officer -
Kurt R Widmer,
Director -
Danielle A Katcher,
Vice President, Marketing -
Kevin R Kelly,
Director -
Timothy P Boyle,
Director -
David J Mickelson,
President & COO -
Companies, Inc.Busch Invest...,
-
Frank H Clement,
Director -
Ann G Widmer,
10% owner -
Anthony J Short,
Director -
Kurt R Widmer Ann G Widmer,
-
Paul S Shipman,
President & CEO -
Michael Loughran,
Director -
Katia Schlienger,
Chief Medical Officer -
Jorn Aldag,
Chief Executive Officer -
Christine D. Baker,
Chief Operating Officer -
Mark Winderlich,
Chief Development Officer -
Mary Theresa Coelho,
EVP and CFO -
Malte Peters,
Chief Executive Officer -
Sean A Cassidy,